Works by van de Velde, Helgi

Results: 52

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Published in:

Journal of Blood Medicine, 2017, v. 8, p. 107, doi. 10.2147/JBM.S102328

By:

A;
Richardson, Paul G.;
Kumar, Shaji;
Laubach, Jacob P.;
Paba-Prada, Claudia;
Gupta, Neeraj;
Berg, Deborah;
van de Velde, Helgi;
Moreau, Philippe

Publication type:

Article

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

Published in:

European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x

By:

Delforge, Michel;
Terpos, Evangelos;
Richardson, Paul G.;
Shpilberg, Ofer;
Khuageva, Nuriet K.;
Schlag, Rudolf;
Dimopoulos, Meletios A.;
Kropff, Martin;
Spicka, Ivan;
Petrucci, Maria T.;
Samoilova, Olga S.;
Mateos, Maria-Victoria;
Magen-Nativ, Hila;
Goldschmidt, Hartmut;
Esseltine, Dixie-Lee;
Ricci, Deborah S.;
Liu, Kevin;
Deraedt, William;
Cakana, Andrew;
van de Velde, Helgi

Publication type:

Article

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

Published in:

European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x

By:

Dimopoulos, Meletios A.;
Mateos, Maria-Victoria;
Richardson, Paul G.;
Schlag, Rudolf;
Khuageva, Nuriet K.;
Shpilberg, Ofer;
Kropff, Martin;
Spicka, Ivan;
Palumbo, Antonio;
Wu, Ka Lung;
Esseltine, Dixie-Lee;
Liu, Kevin;
Deraedt, William;
Cakana, Andrew;
Van De Velde, Helgi;
San Miguel, Jesús F.

Publication type:

Article

Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis.

Published in:

American Journal of Hematology, 2021, v. 96, n. 11, p. E423, doi. 10.1002/ajh.26319

By:

Schjesvold, Fredrik;
Bringhen, Sara;
G. Richardson, Paul;
Perrot, Aurore;
Leleu, Xavier;
Moreau, Philippe;
A. Dimopoulos, Meletios;
Hulin, Cyrille;
Tekle, Christina;
Foster, Meredith C.;
Poole, Elizabeth M.;
van de Velde, Helgi;
Facon, Thierry

Publication type:

Article

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

Published in:

American Journal of Hematology, 2015, v. 90, n. 5, p. E86, doi. 10.1002/ajh.23967

By:

Harrison, Simon J.;
Quach, Hang;
Link, Emma;
Feng, Huaibao;
Dean, Joanne;
Copeman, Michael;
Van De Velde, Helgi;
Schwarer, Anthony;
Baker, Bartrum;
Spencer, Andrew;
Catalano, John;
Campbell, Philip;
Augustson, Bradley;
Romeril, Ken;
Prince, Henry Miles

Publication type:

Article

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

Published in:

American Journal of Hematology, 2015, v. 90, n. 4, p. 314, doi. 10.1002/ajh.23933

By:

Mateos, María Victoria;
Richardson, Paul G.;
Dimopoulos, Meletios A.;
Palumbo, Antonio;
Anderson, Kenneth C.;
Shi, Hongliang;
Elliott, Jennifer;
Dow, Edward;
van de Velde, Helgi;
Niculescu, Liviu;
San Miguel, Jesús F.

Publication type:

Article

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Published in:

American Journal of Hematology, 2015, v. 90, n. 1, p. 42, doi. 10.1002/ajh.23868

By:

Orlowski, Robert Z.;
Gercheva, Liana;
Williams, Cathy;
Sutherland, Heather;
Robak, Tadeusz;
Masszi, Tamás;
Goranova-Marinova, Vesselina;
Dimopoulos, Meletios A.;
Cavenagh, James D.;
Špička, Ivan;
Maiolino, Angelo;
Suvorov, Alexander;
Bladé, Joan;
Samoylova, Olga;
Puchalski, Thomas A.;
Reddy, Manjula;
Bandekar, Rajesh;
van de Velde, Helgi;
Xie, Hong;
Rossi, Jean-Franςois

Publication type:

Article

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

Published in:

Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w

By:

Richardson, Paul G.;
Perrot, Aurore;
Mikhael, Joseph;
Martin, Thomas;
Beksac, Meral;
Spicka, Ivan;
Capra, Marcelo;
D'Agostino, Mattia;
Sonneveld, Pieter;
Bisht, Kamlesh;
Fukao, Taro;
Zhang, Rick;
Tada, Keisuke;
Tekle, Christina;
Macé, Sandrine;
Klippel, Zandra;
van de Velde, Helgi;
Moreau, Philippe

Publication type:

Article

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Published in:

2021

By:

Richardson, Paul G.;
Facon, Thierry;
Bensinger, William I.;
Leleu, Xavier;
Campana, Frank;
Macé, Sandrine;
Chiron, Marielle;
van de Velde, Helgi;
Mikhael, Joseph

Publication type:

Letter

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.

Published in:

Cells (2073-4409), 2024, v. 13, n. 10, p. 879, doi. 10.3390/cells13100879

By:

Grab, Anna Luise;
Kim, Peter S.;
John, Lukas;
Bisht, Kamlesh;
Wang, Hongfang;
Baumann, Anja;
Van de Velde, Helgi;
Sarkar, Irene;
Shome, Debarati;
Reichert, Philipp;
Manta, Calin;
Gryzik, Stefanie;
Reijmers, Rogier M.;
Weinhold, Niels;
Raab, Marc S.

Publication type:

Article

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Published in:

Cells (2073-4409), 2019, v. 8, n. 12, p. 1522, doi. 10.3390/cells8121522

By:

Martin, Thomas G.;
Corzo, Kathryn;
Chiron, Marielle;
van de Velde, Helgi;
Abbadessa, Giovanni;
Campana, Frank;
Solanki, Malini;
Meng, Robin;
Lee, Helen;
Wiederschain, Dmitri;
Zhu, Chen;
Rak, Alexey;
Anderson, Kenneth C.

Publication type:

Article

P1366: SAR442257, A CD38/CD28/CD3 TRISPECIFIC ANTIBODY, POTENTIATES CAR T‐CELL ACTIVITY AGAINST LARGE B‐CELL LYMPHOMA.

Published in:

HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000972352.86009.7f

By:

Reville, Patrick;
Dai, Enyu;
Sheikh, Irtiza;
Deng, Qing;
Henderson, Jared;
Le, Cuong;
Rojas, Estela;
Okwuchi, Chizitara;
Wilson, Ashley;
Parsons, Sydney;
Lockman, Shyanne;
Kim, Peter;
Bisht, Kamlesh;
van de Velde, Helgi;
Wang, Hongfang;
Neelapu, Sattva;
Wang, Linghua;
Green, Michael

Publication type:

Article

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES.

Published in:

2023

By:

Perrot, Aurore;
Richardson, Paul;
Mikhael, Joseph;
Martin, Thomas G.;
Beksac, Meral;
Spicka, Ivan;
Eduardo Capra, Marcelo;
D'agostino, Mattia;
Sonneveld, Pieter;
Bisht, Kamlesh;
Fukao, Taro;
Zhang, Rick;
Tada, Keisuke;
Tekle, Christina;
Macé, Sandrine;
Klippel, Zandra;
van de Velde, Helgi;
Moreau, Philippe

Publication type:

Abstract

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>*</sup>.

Published in:

Leukemia & Lymphoma, 2019, v. 60, n. 1, p. 172, doi. 10.1080/10428194.2017.1321750

By:

Robak, Tadeusz;
Huang, Huiqiang;
Jin, Jie;
Zhu, Jun;
Liu, Ting;
Samoilova, Olga;
Pylypenko, Halyna;
Verhoef, Gregor;
Siritanaratkul, Noppadol;
Osmanov, Evgenii;
Pereira, Juliana;
Mayer, Jiri;
Hong, Xiaonan;
Okamoto, Rumiko;
Pei, Lixia;
Rooney, Brendan;
van de Velde, Helgi;
Cavalli, Franco

Publication type:

Article

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

Published in:

Leukemia & Lymphoma, 2018, v. 59, n. 4, p. 896, doi. 10.1080/10428194.2017.1365855

By:

Drach, Johannes;
Bunworasate, Udomsak;
Masliak, Zvenyslava;
Vilchevskaya, Kateryna;
Robak, Tadeusz;
Pei, Lixia;
Rooney, Brendan;
van de Velde, Helgi;
Cavalli, Franco;
Huang, Huiqiang;
Samoilova, Olga;
Belch, Andrew;
Farber, Charles;
Bosly, André;
Novak, Jan;
Zaucha, Jan;
Dascalescu, Angela

Publication type:

Article

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.

Published in:

Leukemia & Lymphoma, 2017, v. 58, n. 8, p. 1968, doi. 10.1080/10428194.2016.1272688

By:

Skarbnik, Alan P.;
Ma, Esprit;
Lafeuille, Marie-Hélène;
Fortier, Jonathan;
Feldman, Tatyana;
Duh, Mei Sheng;
van de Velde, Helgi;
Niculescu, Liviu;
Bonthapally, Vijayveer;
Goy, André

Publication type:

Article

Use of a claims database to characterize and estimate the incidence rate for Castleman disease.

Published in:

Leukemia & Lymphoma, 2015, v. 56, n. 5, p. 1252, doi. 10.3109/10428194.2014.953145

By:

Munshi, Nikhil;
Mehra, Maneesha;
van de Velde, Helgi;
Desai, Avinash;
Potluri, Ravi;
Vermeulen, Jessica

Publication type:

Article

Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres.

Published in:

British Journal of Haematology, 2014, v. 165, n. 1, p. 39, doi. 10.1111/bjh.12717

By:

Robinson, Don;
Reynolds, Matthew;
Casper, Corey;
Dispenzieri, Angela;
Vermeulen, Jessica;
Payne, Krista;
Schramm, Judy;
Ristow, Kay;
Desrosiers, Marie‐Pierre;
Yeomans, Karen;
Teltsch, Dana;
Swain, Richard;
Habermann, Thomas M.;
Rotella, Philip;
Van de Velde, Helgi

Publication type:

Article

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

Published in:

British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x

By:

Richardson, Paul;
Schlag, Rudolf;
Khuageva, Nuriet;
Dimopoulos, Meletios;
Shpilberg, Ofer;
Kropff, Martin;
Vekemans, Marie-Christiane;
Petrucci, Maria Teresa;
Rossiev, Viktor;
Hou, Jian;
Robak, Tadeusz;
Mateos, Maria-Victoria;
Anderson, Kenneth;
Esseltine, Dixie-Lee;
Cakana, Andrew;
Liu, Kevin;
Deraedt, William;
van de Velde, Helgi;
San Miguel, Jesús F.

Publication type:

Article

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.

Published in:

British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2052, doi. 10.1111/bcp.15123

By:

Thai, Hoai‐Thu;
Gaudel, Nadia;
Cerou, Marc;
Ayral, Geraldine;
Fau, Jean‐Baptiste;
Sebastien, Bernard;
van de Velde, Helgi;
Semiond, Dorothée;
Veyrat‐Follet, Christine

Publication type:

Article

Cluster-10 lung-cancer antibodies recognize NSPs, novel neuro-endocrine proteins associated with membranes of the endoplasmic reticulum.

Published in:

International Journal of Cancer, 1994, v. 57, p. 84, doi. 10.1002/ijc.2910570718

By:

Senden, Nicole H. M.;
Van De Velde, Helgi J. K.;
Broers, Jos L. V.;
Timmer, Erika D. J.;
Roebroek, Anton J. M.;
Van De Ven, Wim J. M.;
Ramaekers, Frans C. S.

Publication type:

Article

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Published in:

2017

By:

Gupta, Neeraj;
Diderichsen, Paul;
Hanley, Michael;
Berg, Deborah;
de Velde, Helgi;
Harvey, R.;
Venkatakrishnan, Karthik;
Diderichsen, Paul M;
Hanley, Michael J;
van de Velde, Helgi;
Harvey, R Donald

Publication type:

journal article

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.

Published in:

Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0

By:

Moreau, Philippe;
Karamanesht, Ievgenii I.;
Donmikova, Natalia;
Kyselyova, Maryna Y.;
Vilchevska, Kateryna V.;
Doronin, Vadim A.;
Schmidt, Alexander;
Hulin, Cyrille;
Leleu, Xavier;
Esseltine, Dixie-Lee;
Venkatakrishnan, Karthik;
Skee, Donna;
Huaibao Feng;
Girgis, Suzette;
Cakana, Andrew;
van de Velde, Helgi;
Deraedt, William;
Facon, Thierry

Publication type:

Article

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Published in:

Clinical Pharmacokinetics, 2011, v. 50, n. 12, p. 781, doi. 10.2165/11594410-000000000-00000

By:

Hellmann, Andrzej;
Rule, Simon;
Walewski, Jan;
Shpilberg, Ofer;
Huaibao Feng;
de Velde, Helgi van;
Patel, Hamina;
Skee, Donna M.;
Girgis, Suzette;
Louw, Vernon J.

Publication type:

Article

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

Published in:

2016

By:

Mateos, Maria-Victoria;
Oriol, Albert;
Martínez-López, Joaquín;
Teruel, Ana-Isabel;
Bengoechea, Enrique;
Palomera, Luis;
de Arriba, Felipe;
Esseltine, Dixie-Lee;
Cakana, Andrew;
Pei, Lixia;
van de Velde, Helgi;
Miguel, Jesus;
Martínez-López, Joaquín;
Miguel, Jesus San

Publication type:

journal article

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3

By:

Bahleda, Rastislav;
Le Deley, Marie-Cécile;
Bernard, Apexa;
Chaturvedi, Shalini;
Hanley, Michael;
Poterie, Audrey;
Gazzah, Anas;
Varga, Andreea;
Touat, Mehdi;
Deutsch, Eric;
Massard, Christophe;
Van De Velde, Helgi;
Hollebecque, Antoine;
Sallansonnet-Froment, Magali;
Ricard, Damien;
Taillia, Hervé;
Angevin, Eric;
Ribrag, Vincent;
Soria, Jean-Charles

Publication type:

Article

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.

Published in:

Cancer Medicine, 2023, v. 12, n. 20, p. 20332, doi. 10.1002/cam4.6619

By:

Bisht, Kamlesh;
Fukao, Taro;
Chiron, Marielle;
Richardson, Paul;
Atanackovic, Djordje;
Chini, Eduardo;
Chng, Wee Joo;
Van De Velde, Helgi;
Malavasi, Fabio

Publication type:

Article

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

Published in:

Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753

By:

Lesokhin, Alexander;
LeBlanc, Richard;
Dimopoulos, Meletios A.;
Capra, Marcelo;
Carlo‐Stella, Carmelo;
Karlin, Lionel;
Castilloux, Jean‐Francois;
Forsberg, Peter;
Parmar, Gurdeep;
Tosikyan, Axel;
Pour, Ludek;
Ribrag, Vincent;
Ribolla, Rossella;
Abdallah, Al‐Ola;
Le Roux, Nadia;
Dong, Liyan;
van de Velde, Helgi;
Mayrargue, Laurent;
Lépine, Lucie;
Macé, Sandrine

Publication type:

Article

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 3869, doi. 10.2147/OTT.S150339

By:

Jin, Jie;
Okamoto, Rumiko;
Yoon, Sung-Soo;
Shih, Lee-Yung;
Zhu, Jun;
Liu, Ting;
Hong, Xiaonan;
Pei, Lixia;
Rooney, Brendan;
van de Velde, Helgi;
Huang, Huiqiang

Publication type:

Article

Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.

Published in:

Experimental Hematology & Oncology, 2024, v. 13, n. 1, p. 1, doi. 10.1186/s40164-024-00578-4

By:

Bisht, Kamlesh;
Merino, Aimee;
Igarashi, Rob;
Gauthier, Laurent;
Chiron, Marielle;
Desjonqueres, Alexandre;
Smith, Eric;
Briercheck, Edward;
Romee, Rizwan;
Alici, Evren;
Vivier, Eric;
O'Dwyer, Michael;
van de Velde, Helgi

Publication type:

Article

A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies.

Published in:

British Journal of Haematology, 2024, v. 205, n. 6, p. 2262, doi. 10.1111/bjh.19784

By:

Zabaleta, Aintzane;
Blanco, Laura;
Kim, Peter S.;
Bisht, Kamlesh;
Wang, Hongfang;
Van de Velde, Helgi;
Lasa, Marta;
Tamariz‐Amador, Luis‐Esteban;
Rodriguez‐Otero, Paula;
San‐Miguel, Jesús;
Paiva, Bruno;
Martín‐Sánchez, Esperanza

Publication type:

Article

A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies.

Published in:

British Journal of Haematology, 2024, v. 205, n. 6, p. 2262, doi. 10.1111/bjh.19784

By:

Zabaleta, Aintzane;
Blanco, Laura;
Kim, Peter S.;
Bisht, Kamlesh;
Wang, Hongfang;
Van de Velde, Helgi;
Lasa, Marta;
Tamariz‐Amador, Luis‐Esteban;
Rodriguez‐Otero, Paula;
San‐Miguel, Jesús;
Paiva, Bruno;
Martín‐Sánchez, Esperanza

Publication type:

Article

Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies.

Published in:

Expert Review of Hematology, 2021, v. 14, n. 12, p. 1099, doi. 10.1080/17474086.2021.1983427

By:

Bisht, Kamlesh;
Walker, Brian;
Kumar, Shaji K.;
Spicka, Ivan;
Moreau, Philippe;
Martin, Tom;
Costa, Luciano J.;
Richter, Joshua;
Fukao, Taro;
Macé, Sandrine;
van de Velde, Helgi

Publication type:

Article

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789

By:

Rachedi, Fatiha;
Koiwai, Kimiko;
Gaudel‐Dedieu, Nadia;
Sebastien, Bernard;
Thai, Hoai‐Thu;
Brillac, Claire;
Fau, Jean Baptiste;
Nguyen, Laurent;
van de Velde, Helgi;
Veyrat‐Follet, Christine;
Semiond, Dorothée

Publication type:

Article

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 928, doi. 10.1002/psp4.12666

By:

Koiwai, Kimiko;
El‐Cheikh, Raouf;
Thai, Hoai‐Thu;
Brillac, Claire;
Fau, Jean‐Baptiste;
Veyrat‐Follet, Christine;
Risse, Marie‐Laure;
van de Velde, Helgi;
Semiond, Dorothée;
Nguyen, Laurent

Publication type:

Article

Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009

By:

Moreau, Philippe;
Parmar, Gurdeep;
Prince, Miles;
Ocio, Enrique M.;
Karanes, Chatchada;
Madan, Sumit;
Oriol, Albert;
Bories, Pierre;
Delforgel, Michel;
Gabrail, Nashat;
Semiondi, Dorothee;
Jia, Nan;
Macé, Sandrine;
Suzan, Florence;
van de Velde, Helgi;
Quach, Hang

Publication type:

Article

P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2

By:

Špicka, Ivan;
Moreau, Philippe;
Martin, Thomas;
Facon, Thierry;
Martinez, Gracia;
Oriol, A.;
Youngil Koh;
Lim, Andrew;
Mikala, Gábor;
Rosiñol, Laura;
Münci Yagci;
Cavo, Michele;
Risse, Marie-Laure;
Asset, Gaëlle;
Macé, Sandrine;
van de Velde, Helgi;
Kwee Yong

Publication type:

Article

P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02334-X

By:

Moreau, Philippe;
Parmar, Gurdeep;
Prince, Miles;
Ocio, Enrique;
Karenes, Chatchada;
Madan, Sumit;
Oriol, A;
Bories, Pierre;
Delforge, Michel;
Galbrail, Nashat;
Semiond, Dorothee;
Jia, Nan;
Macé, Sandrine;
Suzan, Florence;
van de Velde, Helgi

Publication type:

Article

P-196: Isatuximab plus Carfilzomib and Dexamethasone in patients with relapsed Multiple Myeloma and soft-tissue Plasmacytomas: IKEMA subgroup analysis.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S145, doi. 10.1016/S2152-2650(21)02323-5

By:

Hájek, Roman;
Jelinek, Tomas;
Moreau, Philippe;
Martin, Thomas;
Pour, Ludek;
Mikala, Gábor;
Symeonidis, Argiris;
Bringhen, Sara;
Rawlings, Andreea;
Risse, Marie-Laure;
van de Velde, Helgi;
Špicka, Ivan

Publication type:

Article

MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0

By:

Richardson, Paul G.;
Perrot, Aurore;
San-Miguel, Jesus;
Beksac, Meral;
Spicka, Ivan;
Leleu, Xavier;
Schjesvold, Fredrik;
Moreau, Philippe;
Dimopoulos, Meletios A.;
Huang, Jeffrey Shang-Yi;
Minarik, Jiri;
Cavo, Michele;
Prince, H Miles;
Cheng Zheng;
Dubin, Franck;
van De Velde, Helgi;
Anderson, Kenneth C.

Publication type:

Article

Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01572-X

By:

Richardson, Paul G.;
Perrot, Aurore;
San-Miguel, Jesus;
Beksac, Meral;
Spicka, Ivan;
Leleu, Xavier;
Schjesvold, Fredrik;
Moreau, Philippe;
Dimopoulos, Meletios A.;
Huang, Jeffrey Shang-Yi;
Minarik, Jiri;
Cavo, Michele;
Prince, H Miles;
Zheng, Cheng;
Dubin, Franck;
van De Velde, Helgi;
Anderson, Kenneth C

Publication type:

Article

Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e254, doi. 10.1016/j.clml.2019.09.420

By:

Dimopoulos, Meletios A.;
Leleu, Xavier;
Moreau, Philippe;
Attal, Michel;
Richardson, Paul G.;
Liberati, Anna Marina;
Harrison, Simon J.;
Prince, H. Miles;
Ocio, Enrique M.;
Assadourian, Sylvie;
Campana, Frank;
Malinge, Laure;
van de Velde, Helgi;
Yong, Kwee

Publication type:

Article

ICARIA-MM study: efficacy analysis according to prior lines of treatment.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e245, doi. 10.1016/j.clml.2019.09.407

By:

Bringhen, Sara;
Attal, Michel;
Pour, Ludek;
Vorobyev, Vladimir;
Vural, Filiz;
Warzocha, Krzysztof;
Benboubker, Lofti;
Koh, Youngil;
Maisnar, Vladimir;
KARLIN, Lionel;
Pavic, Michel;
Campana, Frank;
Charpentier, Eric;
Menas, Fatima;
van de Velde, Helgi;
Richardson, Paul G.

Publication type:

Article

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e33, doi. 10.1016/j.clml.2019.09.049

By:

Harrison, Simon J.;
Richardson, Paul G.;
Alegre, Adrian;
Simpson, David;
Wang, Ming Chung;
Spencer, Andrew;
Delimpasi, Sossana;
Hulin, Cyrille;
Sunami, Kazutaka;
Facon, Thierry;
Vlummens, Philip;
Yong, Kwee;
Campana, Frank;
Inchauspé, Marlène;
Macé, Sandrine;
Risse, Marie-Laure;
van de Velde, Helgi;
Attal, Michel

Publication type:

Article

The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S337, doi. 10.1016/j.clml.2017.07.153

By:

San Miguel, Jesus;
Echeveste Gutierrez, Maria Asunción;
Špicka, Ivan;
Mateos, María-Victoria;
Song, Kevin;
Craig, Michael;
Bladé, Joan;
Hájek, Roman;
Chen, Christine;
Gupta, Neeraj;
Byrne, Catriona;
Lu, Vickie;
van de Velde, Helgi;
Lonial, Sagar

Publication type:

Article

Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e67, doi. 10.1016/j.clml.2017.03.121

By:

Hou, Jian;
Jin, Jie;
Xu, Yan;
Wu, Depei;
Ke, Xiaoyan;
Daobin, Zhou;
Lu, Jin;
Du, Xin;
Chen, Xiequn;
Li, Junmin;
Liu, Jing;
Gupta, Neeraj;
Hanley, Michael;
Li, Hongmei;
Hua, Zhaowei;
Wang, Bingxia;
Zhang, Xiaoquan;
Wang, Hui;
van de Velde, Helgi;
Richardson, Paul

Publication type:

Article

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes: Post-hoc Analysis of Phase 3 TOURMALINE-MM1 Trial (NCT01564537) in Relapsed/Refractory Multiple Myeloma (RRMM).

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e124, doi. 10.1016/j.clml.2017.03.226

By:

Garderet, Laurent;
Laubach, Jacob;
Stoppa, Anne-Marie;
Parameswaran, Hari;
Cavo, Michele;
Ludwig, Heinz;
Mateos, Maria-Victoria;
Luptakova, Katarina;
Lin, Jianchang;
van de Velde, Helgi;
Berg, Deborah;
Moreau, Philippe;
Richardson, Paul

Publication type:

Article

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

Published in:

Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0501-4

By:

Jian Hou;
Jie Jin;
Yan Xu;
Depei Wu;
Xiaoyan Ke;
Daobin Zhou;
Jin Lu;
Xin Du;
Xiequn Chen;
Junmin Li;
Jing Liu;
Gupta, Neeraj;
Hanley, Michael J.;
Hongmei Li;
Zhaowei Hua;
Bingxia Wang;
Xiaoquan Zhang;
Hui Wang;
van de Velde, Helgi;
Richardson, Paul G.

Publication type:

Article

A COMPARISON OF NSP-RETICULONS WITH CONVENTIONAL NEUROENDOCRINE MARKERS IN IMMUNOPHENOTYPING OF LUNG CANCERS.

Published in:

Journal of Pathology, 1997, v. 182, n. 1, p. 13, doi. 10.1002/(SICI)1096-9896(199705)182:1<13::AID-PATH804>3.0.CO;2-Z

By:

SENDEN, NICOLE H. M.;
TIMMER, ERIKA D. J.;
DE BRUÏNE, ADRIAAN;
WAGENAAR, SJOERD SC.;
VAN DE VELDE, HELGI J. K.;
ROEBROEK, ANTON J. M.;
VAN DE VEN, WIM J. M.;
BROERS, JOS L. V.;
RAMAEKERS, FRANS C. S.

Publication type:

Article

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.

Published in:

European Journal of Haematology, 2024, v. 113, n. 5, p. 593, doi. 10.1111/ejh.14270

By:

Kapoor, Prashant;
Nathwani, Nitya;
Jelinek, Tomas;
Pour, Ludek;
Perrot, Aurore;
Dimopoulos, Meletios‐Athanasios;
Huang, Shang‐Yi;
Spicka, Ivan;
Chhabra, Saurabh;
Lichtman, Eben;
Mateos, Maria‐Victoria;
Kanagavel, Dheepak;
Zhao, Liang;
Guillemin‐Paveau, Helene;
Macé, Sandrine;
van de Velde, Helgi;
Richardson, Paul G.

Publication type:

Article